Korean J Endocr Surg.  2015 Mar;15(1):6-9. 10.16956/kaes.2015.15.1.6.

Updates in Familial Non-Medullary Thyroid Cancer

• Yoon JH

• KMID: 2144007
• DOI: http://doi.org/10.16956/kaes.2015.15.1.6

Abstract

Familial non-medullary thyroid cancer (FNMTC) may be considered as a separate clinical entity with variable aggressive biologic behaviors on the basis of previously published studies. Therefore, a family history of NMTC should be carefully considered as a possible prognostic factor when endocrine surgeons set a plan regarding the extent of surgery, radioactive iodine treatment, and follow-up strategy for FNMTC patients.

Keyword

Familial non-medullary thyroid cancer; Family history

MeSH Terms

Humans
Iodine
Thyroid Neoplasms*
Iodine

Reference

References

1. Sippel RS, Caron NR, Clark OH. An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up. World J Surg. 2007; 31:924–33.

2. Pal T, Vogl FD, Chappuis PO, Tsang R, Brierley J, Renard H, et al. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab. 2001; 86:5307–12.

3. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 1994; 86:1600–8.

4. Ron E, Kleinerman RA, LiVolsi VA, Fraumeni JF Jr. Familial nonmedullary thyroid cancer. Oncology. 1991; 48:309–11.

5. Charkes ND. On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds. Thyroid. 2006; 16:181–6.

6. Charkes ND. On the prevalence of familial nonmedullary thyroid cancer. Thyroid. 1998; 8:857–8.

7. Grossman RF, Tu SH, Duh QY, Siperstein AE, Novosolov F, Clark OH. Familial nonmedullary thyroid cancer. An emerging entity that warrants aggressive treatment. Arch Surg. 1995; 130:892–7.

8. Hemminki K, Li X. Familial risk of cancer by site and histopathology. Int J Cancer. 2003; 103:105–9.

9. Maxwell EL, Hall FT, Freeman JL. Familial nonmedullary thyroid cancer: a matched-case control study. Laryngoscope. 2004; 114:2182–6.

10. Moses W, Weng J, Kebebew E. Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer. Thyroid. 2011; 21:367–71.

11. Vriens MR, Suh I, Moses W, Kebebew E. Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer. Thyroid. 2009; 19:1343–9.

12. Khan A, Smellie J, Nutting C, Harrington K, Newbold K. Familial nonmedullary thyroid cancer: a review of the genetics. Thyroid. 2010; 20:795–801.

13. Hou P, Xing M. Absence of germline mutations in genes within the MAP kinase pathway in familial nonmedullary thyroid cancer. Cell Cycle. 2006; 5:2036–9.

14. Hemminki K, Eng C, Chen B. Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab. 2005; 90:5747–53.

15. Alsanea O, Wada N, Ain K, Wong M, Taylor K, Ituarte PH, et al. Is familial nonmedullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. Surgery. 2000; 128:1043–50.

16. Mazeh H, Benavidez J, Poehls JL, Youngwirth L, Chen H, Sippel RS. In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease. Thyroid. 2012; 22:3–8.

17. Hillenbrand A, Varhaug JE, Brauckhoff M, Pandev R, Haufe S, Dotzenrath C, et al. Familial nonmedullary thyroid carcinoma-clinical relevance and prognosis. A European multicenter study. ESES Vienna presentation. Langenbecks Arch Surg. 2010; 395:851–8.

18. Loh KC. Familial nonmedullary thyroid carcinoma: a meta-review of case series. Thyroid. 1997; 7:107–13.

19. Uchino S, Noguchi S, Kawamoto H, Yamashita H, Watanabe S, Yamashita H, et al. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World J Surg. 2002; 26:897–902.

20. Lupoli G, Vitale G, Caraglia M, Fittipaldi MR, Abbruzzese A, Tagliaferri P, et al. Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet. 1999; 353:637–9.

21. Uchino S, Noguchi S, Yamashita H, Murakami T, Watanabe S, Ogawa T, et al. Detection of asymptomatic differentiated thyroid carcinoma by neck ultrasonographic screening for familial nonmedullary thyroid carcinoma. World J Surg. 2004; 28:1099–102.

22. Robenshtok E, Tzvetov G, Grozinsky-Glasberg S, Shraga-Slutzky I, Weinstein R, Lazar L, et al. Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study. Thyroid. 2011; 21:43–8.

23. Ito Y, Kakudo K, Hirokawa M, Fukushima M, Yabuta T, Tomoda C, et al. Biological behavior and prognosis of familial papillary thyroid carcinoma. Surgery. 2009; 145:100–5.

24. Ito Y, Fukushima M, Yabuta T, Inoue H, Uruno T, Kihara M, et al. Prevalence and prognosis of familial follicular thyroid carcinoma. Endocr J. 2008; 55:847–52.

25. Triponez F, Wong M, Sturgeon C, Caron N, Ginzinger DG, Segal MR, et al. Does familial nonmedullary thyroid cancer adversely affect survival? World J Surg. 2006; 30:787–93.

26. Lee YM, Yoon JH, Yi O, Sung TY, Chung KW, Kim WB, et al. Familial history of nonmedullary thyroid cancer is an independent prognostic factor for tumor recurrence in younger patients with conventional papillary thyroid carcinoma. J Surg Oncol. 2014; 109:168–73.

27. Park YJ, Ahn HY, Choi HS, Kim KW, Park do J, Cho BY. The longterm outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases. Thyroid. 2012; 22:356–62.